Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

St. Baldrick's Foundation and Funding Partners Create New Super Grant to Further Progress in Osteosarcoma Research

(PRNewsfoto/St. Baldrick's Foundation)

News provided by

St. Baldrick's Foundation

Jun 06, 2023, 09:00 ET

Share this article

Share toX

Share this article

Share toX

St. Baldrick's Foundation Celebrates a Partnership for Progress in Osteosarcoma

LOS ANGELES, June 6, 2023 /PRNewswire/ -- For more than 40 years the main treatment for pediatric osteosarcoma has not changed. Patients with this type of aggressive bone cancer, most often diagnosed in teens, are in desperate need of new options. Fewer than 30% of patients survive when osteosarcoma has spread beyond the primary tumor at diagnosis. 

To make a significant impact for kids fighting osteosarcoma, five funding partners have banded together with St. Baldrick's to support a new grant - The Fight Osteosarcoma Together (FOT) Super Grant. Today we are excited to announce that the recipient of this three-year, $1.5 million grant is Dr. Patrick Grohar, at the Children's Hospital of Philadelphia. The goal: a clinical trial to test a new treatment within three years. 

"Our group is honored and humbled to have been selected for this award," says Dr. Grohar. "I have dedicated my life to the care of patients with bone tumors. As you know, we are still using the same, decades-old chemotherapy regimen to treat patients with osteosarcoma."  

Dr. Grohar's goal is to discover targeted therapies for osteosarcoma. One of the major challenges in treating osteosarcoma is the presence of different genetic mutations that drive tumor growth in individual patients. However, a significant percentage (12-39%) of these tumors share a common genetic change known as an amplification in a gene called MYC, which has been linked to aggressive disease and poor prognosis. 

To shed light on this specific subset of osteosarcoma, Dr. Grohar and colleagues will investigate the role of the MYC gene in the development and aggressive nature of the disease. Dr. Grohar plans to find compounds that are not only tailored to MYC-amplified osteosarcoma but are also effective treatment options. The team will explore various approaches, such as utilizing these compounds alone, in combination with chemotherapy, or specifically targeting metastasis prevention (the spread of cancer). 

By delving into this distinct subgroup of osteosarcoma and collaborating with other scientists, Dr. Grohar hopes to discover new ways to treat MYC-amplified osteosarcoma and give patients a better outcome.  

Meet the Funding Partners 

Michael & April Egge 
Michael Egge is a funding partner and one of the driving forces behind this project. "Watching your child survive osteosarcoma, with all its challenges and uncertainties, shook me to my core," he says. "Olivia's experience, and that of the many other children and families I have met along the way, inspire me to stay focused and dig in, because we can and we must do better for children confronting this disease. I am grateful for Olivia's survival, and awed by what she has taught me about resilience, perseverance, and faith, and I pray and hope that we all persevere, lean in, and fight for a cure through creative, large, competitive grants like this." 

Mr. Egge had previously partnered with St. Baldrick's and the Osteosarcoma Collaborative in 2018 to fund a $1.35 million grant for Dr. Alex Huang. 

Osteosarcoma Collaborative 
The Osteosarcoma Collaborative (OSC), which Mr. Egge co-founded, is made up of passionate and dedicated parents, friends and family. It brings together data, researchers, patients and families to find new cures for osteosarcoma. The organization focuses on advocacy, fundraising, education and awareness, and supports new treatment options for osteosarcoma patients. To date, OSC has raised over $1.65 million for osteosarcoma research. 

Founding member and chairperson, Miriam Cohen, lost her son Austin to the disease in 2017. "Austin did nothing wrong, he methodically thought through and endured all of the recommended treatments, always offering someone a smile," she says, "but the lack of medical research failed him." Living through the realization that there were no medical treatments available for Austin motivated her to turn her grief into change by co-founding OSC in 2017 and most recently, spearheading the group's fundraising for this grant. Christiane Robbins, the chief scientific advisor for the group, is a Scientific Review Officer for the National Institutes of Health, whose 18-year-old son David passed away in 2017 to pediatric osteosarcoma. Christiane put her professional background to work as she provided guidance with the scientific review process for the grant. 

Fueled by her son's relentless positivity, OSC Board member Sunita Krishna and the Team Arnav Foundation are supporting OSC in reaching their Fight Osteosarcoma Together Super Grant goal. Founded to honor her son's legacy, the foundation supports groundbreaking research initiatives. Led by Arnav's twin brother, Dhruv, the organization brings together researchers and innovators united in their pursuit of scientific breakthroughs. "My brother was a beacon of hope, let's follow his lead and find the cure." So far Team Arnav has funded close to $150K in research. 

Battle Osteosarcoma 
In 2019, a group of determined moms of children affected by osteosarcoma came together to form Battle Osteosarcoma, an organization helping to blaze new trails in the fight against this devastating disease. In memory of Charlotte, Dylan, and Tyler, three teens from a small community who passed away from osteosarcoma, Battle Osteosarcoma is committed to raising funds to support research for better treatment options and outcomes for osteosarcoma patients and their families. The organization is also focused on investing in the next generation of researchers. Shortly after Battle Osteosarcoma was formed, they teamed up with St. Baldrick's to fund a $1.35 million research grant to support the Sweet-Cordero Lab at the University of California, San Francisco to study a precision oncology approach for relapsed osteosarcoma. The impact of Battle Osteosarcoma's funding to Dr. Sweet-Cordero includes supporting a clinical trial, testing hundreds of drug combinations, developing new models and collaborating with other researchers globally. The results have been transformative and brought much needed attention to osteosarcoma. To date, Battle Osteosarcoma has raised over $2.35 million for osteosarcoma research, thanks to the incredible support of their community. 

Seeing the exciting outcomes in the Huang lab and Sweet Cordero lab, Mr. Egge asked Battle Osteosarcoma, the Osteosarcoma Collaborative, and other like-minded donors to work with St. Baldrick's to make another sizable game-changing pediatric osteosarcoma grant possible, using the same model: a grant selected through a winner-take-all competitive process based strictly on scientific review. This model has a proven track record in translating lab science to clinical trials and patient benefit, with other foundational learning along the way. That made it easier for Mr. Egge to persuade other leading organizations to come together and make the Fight Osteosarcoma Together Super Grant. 

New partners joining to fund this grant are CureSearch for Children's Cancer and the Zach Sobiech Osteosarcoma Fund of Children's Cancer Research Fund. 

CureSearch for Children's Cancer 
In addition to funding, CureSearch played a vital role in the review process, by assessing the clinical translation and drug development potential of the grant. Composed of esteemed leaders from pharmaceutical, biotech, and clinical research organizations, the CureSearch Industry Advisory Council actively champions pediatric cancer drug development, forwarding CureSearch's mission to drive targeted and innovative research with measurable results in an accelerated time frame. 

"Real progress in childhood cancer research requires collaboration, so we are honored to be a funding partner on this award," said Holly Zink, Director of Research and Programs at CureSearch. "Dr. Grohar's project aligns with our laser focus on addressing critical, unmet need in pediatric cancer treatment. We look forward to seeing the impact of this groundbreaking research on pediatric osteosarcoma patients who are counting on novel treatment options." 

The Zach Sobiech Osteosarcoma Fund 
The Zach Sobiech Osteosarcoma Fund, which supports groundbreaking osteosarcoma research nationwide through Children's Cancer Research Fund, is also a funding partner. Before Zach passed away from osteosarcoma in 2013, he and his family started the Zach Sobiech Osteosarcoma Fund, in the hopes that his legacy would make cancer treatment safer and more effective for kids diagnosed after him. His hit song "Clouds," written about his experience of living while knowing he was dying, went viral shortly before his death - proceeds from Zach's music also support his fund. In 2023, Zach's Fund topped $4 million raised since the teen singer/songwriter passed away 10 years ago. To date, it has enabled 16 new discoveries about the genetics of osteosarcoma, brought a national clinical trial to fruition, and now will support The Fight Osteosarcoma Together Super Grant. 

"I often think about a moment during Zach's fight where he was sharing a hospital room with a young boy, who also had cancer," said Laura Sobiech, Zach's mom. "He said to me, 'Mom, if I had to die so that little boy could live, I would.' Ever since, that's been the goal of the Zach Sobiech Osteosarcoma Fund – to use Zach's story and legacy to fund research that will save the lives of kids with osteosarcoma." 

With the collaboration of these funding partners and a stellar group of researchers led by Dr. Grohar, the St. Baldrick's Foundation is excited about this opportunity to advance pediatric osteosarcoma research, paving the way for brighter futures for children battling this disease. 

"We have lit a fire," says Mr. Egge. "Let's add more fuel and make it rage for discovery, innovation and a cure." 

For more information about St. Baldrick's Foundation Grants or ways to get involved, please visit StBaldricks.org.

About St. Baldrick's Foundation 
Every 2 minutes, a child somewhere is diagnosed with cancer. In the U.S., 1 in 5 will not survive. The St. Baldrick's Foundation, the largest charitable funder of childhood cancer research grants, is on a mission to Conquer Kids' Cancer by supporting the most promising research to find cures and better treatments for all childhood cancers. When you give to St. Baldrick's, you don't just give to one hospital – you support virtually every institution with the expertise to treat kids with cancer across the U.S. St. Baldrick's ensures that children fighting cancer now — and those diagnosed in the future — will have access to the most cutting-edge treatment, by supporting every stage of research, from new ideas in the lab to the training of the next generation of researchers, to life-saving clinical trials. Visit StBaldricks.org and help #ConquerKidsCancer. 

SOURCE St. Baldrick's Foundation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Thousands Across the U.S. To Go Bald and Take Action for Childhood Cancer Research This Month

Thousands Across the U.S. To Go Bald and Take Action for Childhood Cancer Research This Month

This March, communities across the U.S. will come together to support the St. Baldrick's Foundation, the largest charity of childhood cancer research ...

Meet the 2025 St. Baldrick's Foundation Ambassadors

Meet the 2025 St. Baldrick's Foundation Ambassadors

The St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants, is proud to introduce its 2025 Ambassadors who along...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Not For Profit

Not For Profit

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.